Illumina Cambridge

Illumina Cambridge Limited serves as the European headquarters and a major research and development hub for Illumina, the global leader in DNA sequencing and array-based technologies. Located at Granta Park in Cambridge, UK, the entity originated from the 2007 acquisition of Solexa, the pioneer of Sequencing-by-Synthesis (SBS) technology that now powers the vast majority of next-generation sequencing (NGS) worldwide. The company provides a comprehensive ecosystem of sequencing instruments, reagents, and bioinformatics software that enables large-scale genomic analysis for research and clinical diagnostics. Its products are foundational to modern precision medicine, supporting critical applications in oncology, reproductive health, and rare disease characterization. As a cornerstone of the UK's life sciences sector, Illumina Cambridge continues to drive innovation in high-throughput genetic measurement and population-scale genomics.